-
Product Insights
Next Generation Sequencing (NGS) Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Next Generation Sequencing (NGS) Tests Pipeline Market Overview Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. Key Territories ·       The US ·       China ·       Global ·       Europe ·       South Korea Key Regulatory Paths ·       510(k) ·       NMPA ·       PMA ·       CE-IVD ·       CLIA Leading Companies ·       4bases SA ·       AccuraGen Inc ·       ACT...
-
Sector Analysis
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The following are some of the key highlights of the HER2 breast cancer clinical trial report: As of February 2024, North America led the HER2- breast cancer clinical trials landscape with more than 32% of the clinical trials conducted there. In 2024, Pfizer conducted the highest number of HER2- breast cancer clinical trials. The HER2- breast...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Each year in the US, more than 19,700 women receive a new diagnosis of ovarian cancer. Â The following are some of the key highlights of the ovarian cancer market: Report deliverables include a PowerPoint report...
-
Product Insights
Cervical Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cervical Cancer Clinical Trials Analysis Market Overview A total of 2,108 Cervical Cancer clinical trials were conducted as of January 2024. The Cervical Cancer clinical trial report provides a comprehensive understanding of the Cervical Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       ...
-
Sector Analysis
Colorectal Cancer in Major Markets by Drug Forecast, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Analysis to 2031
Colorectal Cancer Market Report Overview The colorectal cancer market sales across the 8MM were estimated at $15.8 billion in 2021. The market is expected to achieve a CAGR of more than 3% during 2021-2031. The anticipated approval and launch of 14 pipeline therapies and the label expansions of other agents drive the global colorectal cancer market growth. Colorectal cancer Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Colorectal Cancer Market Forecast Download A Free...
-
Thematic Analysis
Biosimilars in Oncology - Thematic Intelligence
Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you: Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain. Assess the marketed and pipeline products and their uptake across 8MM. Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products. Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars....
-
Product Insights
Gallbladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gall Bladder Cancer Clinical Trial Report Overview A total of 620 Gall Bladder Cancer clinical trials were conducted as of December 2023. The Gall Bladder Cancer clinical trial report provides a comprehensive understanding of the Gall Bladder Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Waldenstrom Macroglobulinemia Clinical Trial Report Overview A total of 709 Waldenstrom Macroglobulinemia clinical trials were conducted as of December 2023. The Waldenstrom Macroglobulinemia clinical trial report provides a comprehensive understanding of the Waldenstrom Macroglobulinemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.